text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 06월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한올바이오파마(주)\n상장\n-\n인수\n116,111,366\n16,115,745\n31\n116,111,366\n-\n-\n-\n16,115,745\n31\n116,111,366\n219,483,648\n19,863,538\n힐리언스\n비상장\n-\n인수\n27,310,924\n2,753,300\n76\n14,434,620\n-\n-\n-1,426,312\n2,753,300\n76\n13,008,308\n31,160,612\n-2,964,072\nDaewoong Pharma PHILIPPINES, INC.\xa0\n비상장\n-\n설립\n260,539\n-\n100\n260,539\n-\n-\n-\n-\n100\n260,539\n2,610,449\n253,627\nDaewoong Pharmaceutical(Thailand)Co.,Ltd.\xa0\n비상장\n-\n설립\n205,389\n-\n100\n205,389\n-\n-\n-\n-\n100\n205,389\n3,542,105\n727,562\nPT. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA\n비상장\n-\n설립\n7,812,111\n-\n100\n7,812,111\n6,993,141\n6,993,141\n-\n6,993,141\n100\n14,805,252\n2,386,331\n-707,166\nDAEWOONG PHARMACEUTICAL HONGKONG\n비상장\n-\n설립\n17,660,725\n269,255,424\n90\n37,184,429\n-\n-\n-\n269,255,424\n90\n37,184,429\n41,979,007\n-14,814\n북경대웅위업의약과기유한공사\n비상장\n-\n설립\n9,152,033\n-\n100\n5,827,684\n-\n-\n-\n-\n100\n5,827,684\n4,193,618\n734,568\n바이오시네틱스\n비상장\n-\n사업관련\n2,000,000\n645,000\n18\n819,086\n-\n-\n-\n645,000\n18\n819,086\n2,139,099\n-1,473,558\n이피피미디어\n비상장\n-\n사업관련\n1,000,000\n100,000\n20\n-\n-\n-\n-\n100,000\n20\n-\n6,815,780\n-296,971\n엠디웰아이엔씨\n비상장\n-\n설립\n500,000\n100,000\n50\n500,000\n-\n-\n-\n100,000\n50\n500,000\n9,829,663\n1,669,222\nDaewoong America, Inc.\xa0\n비상장\n2009.12.30\n설립\n825,005\n-\n100\n83,286\n-\n-\n-\n-\n100\n83,286\n97,102\n84,033\nDaewoong Pharmaceutical India Pvt.,Ltd\xa0\n비상장\n-\n설립\n550,733\n-\n100\n550,733\n-\n-\n-\n-\n100\n550,733\n849,678\n225,637\nDAEWOONG PHARMACEUTICAL JAPAN CO.,LTD\n-\n2017.03.08\n설립\n555,621\n1,100\n100\n555,621\n-\n-\n-\n1,100\n100\n555,621\n7,671,649\n659,692\n건강한삶기술창업벤처PEF\n-\n2018.03.19\n설립\n2,500,000\n2,500,000,000\n50\n2,500,000\n-\n-\n-\n2,500,000,000\n50\n2,500,000\n4,658,995\n-145,967\n㈜다나아데이터\n비상장\n2018.11.23\n설립\n5,100,000\n102,000\n51\n5,100,000\n-\n-\n-\n102,000\n51\n5,100,000\n10,127,138\n139,274\nImmplacate, Inc.\n비상장\n2019.03.08\n사업관련\n1,125,970\n1,428,571\n20\n1,125,970\n-\n-\n-\n1,428,571\n20\n1,125,970\n26,949\n-187,662\n아피셀테라퓨틱스\n비상장\n2020.01.23\n설립\n1,960,780\n1,960,780\n54\n1,960,780\n1,577,528\n7,020,000\n-\n3,538,308\n82\n8,980,780\n5,688,129\n-1,174,712\n아이엔테라퓨틱스\n비상장\n2020.05.27\n설립\n3,118,330\n17,414,405\n100\n3,118,330\n-\n-\n-\n17,414,405\n100\n3,118,330\n2,125,940\n-2,566,132\nEvolus.INC(해외상장)(주3)\n-\n2021.03.23\n사업관련\n-\n-\n-\n-\n3,136,869\n57,099,225\n-12,259,251\n3,136,869\n7\n44,839,974\n209,068\n-163,013\n진켐 (주4)\n비상장\n-\n사업관련\n559,660\n41,932\n3\n475,551\n-\n-\n-\n41,932\n3\n475,551\n17,124,130\n-6,055,033\n바이오넷\xa0\n비상장\n2001.12.22\n사업관련\n1,207,646\n324,480\n3\n227,136\n-\n-\n-\n324,480\n3\n227,136\n15,420,980\n124,314\n큐어바이오\xa0\n비상장\n-\n사업관련\n217,377\n3,111\n2\n308,101\n-\n-\n-\n3,111\n2\n308,101\n11,886,803\n-2,895,288\n3D Matrix (해외상장)(주2)\n-\n-\n사업관련\n1,362,230\n320,000\n2\n974,980\n-\n-\n356,229\n320,000\n2\n1,331,209\n29,840\n-27,650\n카이페리온\n비상장\n2019.10.16\n단순투자\n1,000,020\n28,572\n3\n1,000,020\n-\n-\n-\n28,572\n3\n1,000,020\n5,018,113\n-1,224,456\nJTBC\n비상장\n-\n단순투자\n3,000,000\n600,000\n1\n166,800\n-\n-\n-\n600,000\n1\n166,800\n401,083,935\n-25,497,001\n향남제약공단\n비상장\n-\n단순투자\n217,879\n-\n-\n217,879\n-\n-\n-\n-\n-\n217,879\n0\n0\n자일자동차판매\n비상장\n-\n단순투자\n827,695\n-\n0\n200,098\n-\n-\n-\n-\n0\n200,098\n285,973,505\n19,763,288\n인벤티지랩\n비상장\n2020.04.28\n단순투자\n999,995\n83,326\n1\n999,995\n-\n-\n-\n83,326\n1\n999,995\n22,337,134\n-12,880,030\n입셀\n비상장\n2020.09.09\n단순투자\n2,000,002\n9,091\n9\n2,000,002\n-\n-\n-\n9,091\n9\n2,000,002\n58,101\n-114,828\n데일리 임파워링 바이오 헬스케어 펀드4호\n-\n2020.09.23\n단순투자\n1,000,000\n1,000\n7\n1,000,000\n-\n-\n319,065\n1,000\n7\n1,319,065\n15,235,722\n-70,585\n서울의료정보연구소\n-\n2020.12.11\n단순투자\n200,063\n1,067\n6\n200,063\n-\n-\n-\n1,067\n6\n200,063\n297,475\n-310,550\nNeurogastrx(주3)\n-\n2021.06.18\n단순투자\n-\n-\n-\n-\n4,782,095\n4,569,923\n-\n4,782,095\n5\n4,569,923\n10,707\n-3,000\n온코크로스\n비상장\n2021.04.01\n단순투자\n-\n-\n-\n-\n13,214\n1,000,036\n-\n13,214\n1\n1,000,036\n18,708,828\n-12,821,021\n합 계\n-\n-\n205,920,569\n16,502,847\n76,682,325\n-13,010,269\n2,827,791,751\n1,335\xa0\n269,592,625\n1,148,780,233\xa0\n-27,348,754\n(주1) 상기 최근사업연도 재무현황은 20년 기말 재무제표 기준입니다.(주2) 3D Matrix의 재무현황 표기 단위는 천엔입니다.(주3) Evolus, Neurogastrx의 재무현황 표기 단위는 천달러입니다.(주4) 19년 기말 재무현황입니다.\n* 장부가액 감액 사유\n(단위 : 천원)\n법인명\n감액금액\n감액 사유\nEvolus.INC\n(12,259,251)\n시가평가에 따른 공정가치 감소\n\xa0\n']"
